

4 April, 2022

To:
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

This announcement is not an offer to purchase, a solicitation of an offer to purchase, an offer to sell, or a solicitation of an offer to sell the FCC Bonds. This announcement does not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law. This announcement is not for release, publication or distribution in or into, or to any person resident and/or located in, any jurisdiction where such release, publication or distribution is unlawful.

This announcement does not constitute an offer to sell or the solicitation of an offer to purchase any securities in the United States, India or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus which will contain detailed information about the Company and its management, as well as its financial statements. No public offering of securities is to be made by the Company in the United States.

Dear Sirs/Madams,

Re: Intimation of Operations Committee Meeting to authorize the repurchase of outstanding U.S.\$200,000,000 2.00 per cent. Resettable Onward Starting Equity-linked Securities Due 2022 ("Bonds") by Glenmark Pharmaceuticals Limited (the "Company") and issuance of the Notice of Early Redemption by the Company to the holders of the Bonds

We hereby inform you that, pursuant to applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, that Operations Committee by the Board of Directors of the Company in their meeting held today, approved *inter alia* (i) the repurchase of an aggregate principal amount of US\$75,000,000 of the US\$200,000,000 2.00 per cent. (ISIN: XS1426780125; Common Code: 142678012) (the "**Bonds**") (the "**Repurchase**") via on-market purchases; and (ii) the issuance of a notice of early redemption in accordance with the terms of the Trust deed dated June 28, 2016 ("Trust Deed"), constituting the Bonds, by the Company, to the holders of its outstanding Bonds, to redeem the Notes in full at an Early Redemption Amount plus interest accrued but unpaid to the Redemption Date pursuant to Condition 8.2 (*Redemption at the option of the Issuer*) of the terms and conditions of the Bonds.

This is for the information of your members and all concerned in compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended.

The Operations Committee Meeting commenced at 5:45 p.m. and concluded at 6:15 p.m.

The above is for your information.

Thank you.

Yours faithfully,
For Glenmark Pharmaceuticals Limited


Harish Kuber
Company Secretary and Compliance Officer

Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

